You are here

The Role of T-VEC and Other Intralesional Agents

Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, discusses the place in therapy of talimogene laherparepvec (T-VEC) and other intralesional oncolytic agents for melanoma patients, both as monotherapy and in combination with treatments including checkpoint inhibitors.

American Society of Clinical Oncology, June 2016